HomeCompareCSBTF vs VIG

CSBTF vs VIG: Dividend Comparison 2026

CSBTF yields 7.18% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VIG wins by $187.00 in total portfolio value· pulled ahead in Year 10
10 years
CSBTF
CSBTF
● Live price
7.18%
Share price
$27.85
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.2K
Annual income
$1,132.80
Full CSBTF calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — CSBTF vs VIG

📍 VIG pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSBTFVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSBTF + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSBTF pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSBTF
Annual income on $10K today (after 15% tax)
$610.41/yr
After 10yr DRIP, annual income (after tax)
$962.88/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, CSBTF beats the other by $810.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSBTF + VIG for your $10,000?

CSBTF: 50%VIG: 50%
100% VIG50/50100% CSBTF
Portfolio after 10yr
$32.3K
Annual income
$655.98/yr
Blended yield
2.03%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSBTF buys
0
VIG buys
0
No recent congressional trades found for CSBTF or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSBTFVIG
Forward yield7.18%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$32.2K$32.4K
Annual income after 10y$1,132.80$179.15
Total dividends collected$9.3K$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CSBTF vs VIG ($10,000, DRIP)

YearCSBTF PortfolioCSBTF Income/yrVIG PortfolioVIG Income/yrGap
1$11,418$718.13$11,304$163.92+$114.00CSBTF
2$12,984$766.33$12,759$166.33+$225.00CSBTF
3$14,707$814.40$14,382$168.52+$325.00CSBTF
4$16,599$862.14$16,192$170.52+$407.00CSBTF
5$18,670$909.37$18,210$172.34+$460.00CSBTF
6$20,933$955.93$20,460$173.98+$473.00CSBTF
7$23,400$1,001.68$22,968$175.48+$432.00CSBTF
8$26,084$1,046.47$25,763$176.83+$321.00CSBTF
9$29,000$1,090.21$28,878$178.05+$122.00CSBTF
10← crossover$32,163$1,132.80$32,350$179.15$187.00VIG

CSBTF vs VIG: Complete Analysis 2026

CSBTFStock

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.

Full CSBTF Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this CSBTF vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSBTF vs SCHDCSBTF vs JEPICSBTF vs OCSBTF vs KOCSBTF vs MAINCSBTF vs DGROCSBTF vs NOBLCSBTF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.